VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
GDRXGoodRx Holdings, Inc.
$2.66$922M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksGDRXP/E History

GDRX logoGoodRx Holdings, Inc. (GDRX) P/E Ratio History

Deep Value

Trading at 31.2x · 11th percentile of 5-year range · Significant discount to historical valuation · Data 2020–2026

Current P/E (TTM)
31.2x
-97% vs 5Y avg
5Y Avg P/E
927.3x
Median 47.4x
5Y Percentile
11th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
31.2x
Min23.1xMedian47.4xMax7722.2x
TTM EPS$0.09
Price$2.66
Earnings Yield3.21%
EPS Growth (1Y)104.1%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, GoodRx Holdings, Inc. (GDRX) trades at a price-to-earnings ratio of 31.2x, with a stock price of $2.66 and trailing twelve-month earnings per share of $0.09.

The current P/E is 97% below its 5-year average of 927.3x. Over the past five years, GDRX's P/E has ranged from a low of 23.1x to a high of 7722.2x, placing the current valuation at the 11th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, GDRX trades at a 41% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, GDRX commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GDRX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GDRX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
31.2vs22.1
+41%
Above Sector
vs. S&P 500
31.2vs24.4
+28%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 104% EPS growth (1Y)

GDRX P/E vs Peers

Patient Engagement, Intake and Payments peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
HIMS logoHIMSHims & Hers Health, Inc.
$8B69.5--4%
OPRX logoOPRXOptimizeRx Corporation
$93M18.4Lowest-+125%Best
DOCS logoDOCSDoximity, Inc.
$4B20.90.40Best-12%
PGNY logoPGNYProgyny, Inc.
$2B40.15.99+14%
CVS logoCVSCVS Health Corporation
$125B70.7--62%
MCK logoMCKMcKesson Corporation
$90B19.6-+49%
CAH logoCAHCardinal Health, Inc.
$52B34.4-+87%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

GDRX Historical P/E Data (2020–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$1.96$0.0823.1x-98%
FY2025 Q4Dec 31 2025$2.71$0.0931.8x-97%
FY2025 Q3-$4.23$0.0947.4x-95%
FY2025 Q2Jun 30 2025$4.98$0.1242.3x-95%
FY2025 Q1Mar 31 2025$4.41$0.1043.4x-95%
FY2024 Q4-$4.65$0.0767.4x-93%
FY2023 Q3Sep 30 2023$5.63$0.03165.1x-82%
FY2023 Q2Jun 30 2023$5.52$0.03202.9x-78%
FY2020 Q3Sep 30 2020$55.60$0.017722.2x+733%

Average P/E for displayed period: 927.3x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

6+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

GDRX — Frequently Asked Questions

Quick answers to the most common questions about buying GDRX stock.

What is GDRX's P/E ratio?

GoodRx Holdings, Inc. (GDRX) trailing twelve-month P/E ratio is 31.2x, based on TTM diluted EPS of $0.09. The 5-year average P/E is 927.3x and the historical range spans 23.1x to 7722.2x.

Is GDRX stock overvalued or undervalued?

GDRX trades at 31.2x P/E, below its 5-year average of 927.3x. At the 11th percentile of its historical range (23.1x–7722.2x), the stock is priced at a discount to its own history.

Is GDRX stock expensive?

No, GDRX is not expensive on a historical basis. The current P/E of 31.2x is below the 5-year average of 927.3x and sits at the 11th percentile of its valuation range.

What is GDRX's historical P/E range?

Over the past 5 years, GDRX's P/E ratio has ranged from 23.1x to 7722.2x, with a median of 47.4x and an average of 927.3x. The current P/E of 31.2x places the stock at the 11th percentile of this range. Full historical data spans 2020–2026.

How does GDRX's P/E compare to the S&P 500?

GDRX trades at 31.2x P/E versus the S&P 500 median of 24.4x. The 28% premium to the market typically reflects higher expected earnings growth or quality.

How does GDRX's valuation compare to Healthcare peers?

GoodRx Holdings, Inc. P/E of 31.2x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is GDRX's PEG ratio?

GDRX PEG ratio is N/A, based on a P/E of 31.2x and EPS growth of 104.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is GDRX's earnings yield?

GDRX earnings yield is 3.21%, the inverse of its 31.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

GDRX P/E Ratio History (2020–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current23.1x
Period Avg927.3x
Range23.1x - 7722.2x
Change-100%
9 quartersSep 30, 2020 - Mar 31, 2026